U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503652) titled 'Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis' on March 25.
Brief Summary: Palmoplantar pustulosis (PPP) is a chronic and recurrent skin disease, mainly characterized by erythema, pustules and scales on the palms and soles, often accompanied by itching and pain, which seriously affects the quality of life of patients. Currently, the treatment options for PPP are limited. Traditional therapies such as topical glucocorticoids, phototherapy and oral immunosuppressants have unsatisfactory efficacy, and long-term use may cause significant side effects. The introduction of biologics has...